Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Neutral
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.2.9188.7772
Address
Level 14 264-278 George Street Australia Square Sydney, New South Wales (NSW) 2000
Description
Next Science Ltd. engages in the research, development, and distribution of technologies with bacterial issue application. It operates through the North America, Australia and New Zealand geographical segments. The company was founded by Matthew Myntti on October 20, 2017 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.08 - 0.5
Trade Value (12mth)
US$5,375.00
1 week
5%
1 month
-12.5%
YTD
-8.7%
1 year
-72.73%
All time high
4.73
EPS 3 yr Growth
-23.60%
EBITDA Margin
-39.70%
Operating Cashflow
-$8m
Free Cash Flow Return
-83.20%
ROIC
-110.60%
Interest Coverage
-41.90
Quick Ratio
1.70
Shares on Issue (Fully Dilluted)
292m
HALO Sector
Healthcare
Next Company Report Date
04-Mar-26
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
14 March 25 |
Notice of Change of Share Registry
×
Notice of Change of Share Registry |
11 March 25 |
2025 Annual General Meeting - Notification of dates
×
2025 Annual General Meeting - Notification of dates |
03 March 25 |
Change in substantial holding from TEK
×
Change in substantial holding from TEK |
03 March 25 |
Change in substantial holding from Tiga Trading Pty Ltd
×
Change in substantial holding from Tiga Trading Pty Ltd |
28 February 25 |
FY24 Appendix 4E and Financial Report
×
FY24 Appendix 4E and Financial Report |
28 February 25 |
Next Science reports FY24 Result
×
Next Science reports FY24 Result |
28 February 25 |
FY24 Annual Result Investor Presentation
×
FY24 Annual Result Investor Presentation |
25 February 25 |
Next Science receives FDA Warning Letter
×
Next Science receives FDA Warning Letter |
07 February 25 |
Notice of FY24 Result and Investor Webinar
×
Notice of FY24 Result and Investor Webinar |
29 January 25 |
Notification of cessation of securities - NXS
×
Notification of cessation of securities - NXS |
23 January 25 |
Appendix 4C & Quarterly Activity Report - 31 December
×
Appendix 4C & Quarterly Activity Report - 31 December |
20 January 25 |
Notice of 4Q FY24 Result and Investor Webinar
×
Notice of 4Q FY24 Result and Investor Webinar |
08 January 25 |
Pause in Trading
×
Pause in Trading |
08 January 25 |
Litigation involving former employee
×
Litigation involving former employee |
28 October 24 |
Publication of XPERIENCE study showing 0% infection rate
×
Publication of XPERIENCE study showing 0% infection rate |
24 October 24 |
NXS Presentation - Wilsons Drug & Device Conference
×
NXS Presentation - Wilsons Drug & Device Conference |
22 October 24 |
Appendix 4C & Quarterly Activity Report - 30 September 2024
×
Appendix 4C & Quarterly Activity Report - 30 September 2024 |
16 October 24 |
Notice of 3Q FY24 Result and Investor Webinar
×
Notice of 3Q FY24 Result and Investor Webinar |
20 September 24 |
Notification of cessation of securities - NXS
×
Notification of cessation of securities - NXS |
20 September 24 |
Notification regarding unquoted securities - NXS
×
Notification regarding unquoted securities - NXS |
20 September 24 |
Notification regarding unquoted securities - NXS
×
Notification regarding unquoted securities - NXS |
20 September 24 |
Appendix 3Y - I.V. Hall
×
Appendix 3Y - I.V. Hall |
30 August 24 |
Half Year Report & Appendix 4D
×
Half Year Report & Appendix 4D |
30 August 24 |
Next Science reports 1H FY24 Result
×
Next Science reports 1H FY24 Result |
30 August 24 |
1H FY24 Result Presentation
×
1H FY24 Result Presentation |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.